Steve Tuplin/LinkedIn
Dec 6, 2025, 11:50
Steve Tuplin on Roche’s Mission at ASH25
Steve Tuplin, VP, Global Disease Area Head – Hematology and ai Oncology at Roche, shared on LinkedIn:
”Next stop: Orlando!
While many head there for the thrill rides, we are heading to ASH25 for a different kind of excitement: the breakthroughs shaping the future of haematology.
We are looking forward to sharing how our broad portfolio is evolving to meet the real-world needs of patients and the healthcare system.
It’s not about magic; it’s about our unwavering commitment to raising the therapeutic bar and delivering innovation that truly matters.
I’m excited to catch up with those of you attending.
Let me know—what is top of your list for this year?”
All from ASH25 featured in Hemostasis Today.
-
Jan 25, 2026, 15:57Céline Chapelle Shares Clinical Predictors From the API-CAT Trial
-
Jan 25, 2026, 15:42Francesco Lo Monaco on Heart Disease Starting Quiet While Your Labs Speak First
-
Jan 25, 2026, 15:33Wilfried Dinh: Why Heart Patients Still Have Events Despite ”Optimal” Cardiovascular Therapy
-
Jan 25, 2026, 15:25Muhammad Ibrahim on Efficacy and Safety of Extended DOACs Use in VTE
-
Jan 25, 2026, 15:08Tushar Pandey on Managing Thrombotic Thrombocytopenic Purpura
-
Jan 25, 2026, 14:55Carolina Contreras Cuevas Shares a Nationwide Study on VTE in PAD
-
Jan 25, 2026, 14:40Jeannie Devereaux Links PRP and Physical Therapy
-
Jan 25, 2026, 14:25Heghine Khachatryan on Anticoagulation After AFib Ablation: New Evidence from NEJM
-
Jan 25, 2026, 12:42Lale Tokgözoğlu on Cardiovascular Risk Factors in Women